Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
Fady Ibraham Malik, Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 2,000 shares of common stock on August 5, 2025, at a price of $36.34, totaling $72,680.
On the same day, Malik also exercised options to acquire 2,000 shares of Cytokinetics common stock at $10.60 per share, for a total value of $21,200.
Following these transactions, Malik directly owns 140,610 shares of Cytokinetics Inc.
In other recent news, Cytokinetics has been the subject of several analyst reports and developments. Stifel analysts maintained their Buy rating and $87 price target for Cytokinetics, expressing confidence after the successful MAPLE-HCM trial, where aficamten showed superiority over beta-blockers for obstructive hypertrophic cardiomyopathy (oHCM). Meanwhile, Raymond (NSE:RYMD) James downgraded Cytokinetics from Outperform to Market Perform, citing concerns about the company’s near-term outlook despite its long-term potential. JPMorgan also adjusted its expectations, lowering the price target to $53 from $71, based on revised revenue forecasts and a gradual launch for aficamten. Mizuho (NYSE:MFG) Securities reduced its price target to $84 from $103, following a delay in the Prescription Drug User Fee Act (PDUFA) date for aficamten to December 2025. Despite this, Mizuho continues to recommend the stock with an Outperform rating. These developments reflect a mix of cautious optimism and strategic adjustments among analysts regarding Cytokinetics’ future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.